Major randomised trials in cancer-associated thrombosis treatment
| Trial | Year | Patients n | Drugs evaluated | Major findings |
| CANTHANOX [35] | 2002 | 146 | Enoxaparin versus warfarin | Statistical tendency of warfarin to be more associated with major bleeding (p=0.09) and death (p=0.07) than enoxaparin. |
| CLOT [36] | 2003 | 672 | Dalteparin versus warfarin | Dalteparin was superior to warfarin in VTE recurrence (p=0.002). No difference in major bleeding or mortality. |
| CATCH [37] | 2015 | 900 | Tinzaparin versus warfarin | Statistical tendency of VTE recurrence reduction with tinzaparin (p=07). No difference in major bleeding or mortality. |
| HOKUSAI-CANCER [45] | 2018 | 1046 | Edoxaban versus dalteparin | Edoxaban was non-inferior to dalteparin. Statistical tendency of superiority of edoxaban in VTE recurrence reduction (p=0.09), statistically significant more major bleeding with edoxaban (p=0.04). |
| SELECT-D [47] | 2018 | 406 | Rivaroxaban versus dalteparin | Statistically significant less VTE recurrence (HR 0.43, 95% CI 0.19–0.99) and statistical tendency of more bleeding (HR 1.83, 95% CI 0.68–4.96) with rivaroxaban (oesophagus and gastro-oesophageal junction cancer patients excluded after inclusion of the first 220 patients) |
| CARAVAGGIO [48] | 2019 (expected) | 1168 (expected) | Apixaban versus dalteparin | ? |
VTE: venous thromboembolism.